308 related articles for article (PubMed ID: 29431876)
1. Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.
Zecca C; Roth S; Findling O; Perriard G; Bachmann V; Pless ML; Baumann A; Kamm CP; Lalive PH; Czaplinski A
Eur J Neurol; 2018 May; 25(5):762-767. PubMed ID: 29431876
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A
Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.
Biernacki T; Sandi D; Füvesi J; Fricska-Nagy Z; Kincses TZ; Ács P; Rózsa C; Dobos E; Cseh B; Horváth L; Nagy Z; Csányi A; Kovács K; Csépány T; Vécsei L; Bencsik K;
PLoS One; 2022; 17(4):e0267346. PubMed ID: 35452476
[TBL] [Abstract][Full Text] [Related]
5. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of fingolimod in a Portuguese real-world population.
Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J; Meca-Lallana V; Barrero F; Martinez-Gines ML; Marzo-Sola ME; Ricart J; Garcia E; En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN
Rev Neurol; 2018 Sep; 67(5):157-167. PubMed ID: 30047118
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
11. Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina.
Patrucco L; Cristiano E; Sánchez F; Miguez J; Rojas JI
Clin Neuropharmacol; 2019; 42(5):163-166. PubMed ID: 31348014
[TBL] [Abstract][Full Text] [Related]
12. The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.
Ziemssen T; Kern R; Cornelissen C
BMC Neurol; 2015 Jun; 15():93. PubMed ID: 26084334
[TBL] [Abstract][Full Text] [Related]
13. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Al Malik Y; Meftah I
Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B
Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
[TBL] [Abstract][Full Text] [Related]
17. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ;
PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
J Neurol; 2021 Mar; 268(3):941-949. PubMed ID: 32974794
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
Braune S; Lang M; Bergmann A;
J Neurol; 2016 Feb; 263(2):327-333. PubMed ID: 26645389
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]